MX2022014468A - Tratamiento para la amiloidosis. - Google Patents

Tratamiento para la amiloidosis.

Info

Publication number
MX2022014468A
MX2022014468A MX2022014468A MX2022014468A MX2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A MX 2022014468 A MX2022014468 A MX 2022014468A
Authority
MX
Mexico
Prior art keywords
amyloidosis
treatment
compounds
formula
amyloid
Prior art date
Application number
MX2022014468A
Other languages
English (en)
Spanish (es)
Inventor
Peter Qinhua Huang
Kevin Duane Bunker
Joseph Robert Pinchman
Ahmed Abdi Samatar
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022014468A publication Critical patent/MX2022014468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022014468A 2020-05-19 2021-05-17 Tratamiento para la amiloidosis. MX2022014468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (1)

Publication Number Publication Date
MX2022014468A true MX2022014468A (es) 2023-02-09

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014468A MX2022014468A (es) 2020-05-19 2021-05-17 Tratamiento para la amiloidosis.

Country Status (12)

Country Link
US (1) US20230210846A1 (enExample)
EP (1) EP4138837A4 (enExample)
JP (1) JP2023527741A (enExample)
KR (1) KR20230013102A (enExample)
CN (1) CN116133661A (enExample)
AU (1) AU2021273731A1 (enExample)
BR (1) BR112022023486A2 (enExample)
CA (1) CA3183746A1 (enExample)
IL (1) IL298297A (enExample)
MX (1) MX2022014468A (enExample)
TW (1) TW202207931A (enExample)
WO (1) WO2021236543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087261A1 (en) * 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Benzamide compounds
US20210154368A1 (en) * 2018-04-09 2021-05-27 Case Western Reserve University Bioink and crosslinkable support medium for printing
DK3774591T3 (da) * 2018-04-10 2023-03-20 Ddp Specialty Electronic Materials Us Llc Dispenser til dåse med fast ventilspindelhus
US10511808B2 (en) * 2018-04-10 2019-12-17 Facebook, Inc. Automated cinematic decisions based on descriptive models

Also Published As

Publication number Publication date
EP4138837A1 (en) 2023-03-01
CN116133661A (zh) 2023-05-16
TW202207931A (zh) 2022-03-01
EP4138837A4 (en) 2024-05-22
WO2021236543A1 (en) 2021-11-25
JP2023527741A (ja) 2023-06-30
BR112022023486A2 (pt) 2023-01-10
AU2021273731A1 (en) 2022-12-15
CA3183746A1 (en) 2021-11-25
IL298297A (en) 2023-01-01
US20230210846A1 (en) 2023-07-06
KR20230013102A (ko) 2023-01-26

Similar Documents

Publication Publication Date Title
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
TW200730523A (en) Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
TW200716141A (en) Compositions and methods for treatment for neoplasms
MX2022003537A (es) Terapias de combinacion.
EP3914604A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT, PREVENTION OR REVERSE OF AGE-RELATED INFLAMMATION AND DISEASE
CR20240120A (es) Compuesto inductor de la degradación de PLK1 novedoso
MX2022013006A (es) Inhibidor de bcl-2.
SA521430751B1 (ar) Kcnt1 مثبطات وطرق استخدامها
MY209340A (en) Egfr inhibitor for the treatment of cancer
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
BRPI0517135A (pt) composições e métodos para tratar doenças neoplásticas
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
DE602005025517D1 (de) Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas
WO2008137102A3 (en) Methods of modulating amyloid beta and compounds useful therefor
CR20240296A (es) Inhibidores parp1
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
SA522441857B1 (ar) مركبات ربط سيريبلون، توليفات منها، وطرق للمعالجة باستخدامها
CY1124762T1 (el) Αναστολεις πρωτεïνης δεσμευσης creb (cbp)
MX2022002751A (es) Tratamiento de la abstinencia de opioides.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
ZA202105742B (en) Modulators of malat1 expression